Imatinib Mesylate in Philadelphia Chromosome-Positive Leukemia of Childhood Review uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Leukemia, Myeloid, Chronic-Phase
  • Philadelphia Chromosome
  • Piperazines
  • Pyrimidines

abstract

  • Imatinib mesylate was found to be effective in inducing undetectable residual disease in a small cohort of pediatric patients with Ph+ leukemia. Further studies of the use of imatinib in childhood Ph+ malignancies are needed.

publication date

  • December 15, 2003

Research

keywords

  • Review

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/cncr.11895

PubMed ID

  • 14669284

Additional Document Info

start page

  • 2643

end page

  • 50

volume

  • 98

number

  • 12